Viatris, Cipla and Aurobindo sign up to make generics of GSK’s long-acting HIV PrEP drug


In a significant development for HIV prevention, Viatris, Cipla, and Aurobindo have partnered with GlaxoSmithKline (GSK) to produce generic versions of GSK’s long-acting pre-exposure prophylaxis (PrEP) drug. This collaboration aims to increase access to this crucial HIV prevention tool by making it more affordable and available to a wider population. In this blog post, we will explore the key points of this partnership, highlighting the potential impact on HIV prevention efforts and global healthcare accessibility.

Key Points:

1. Long-Acting PrEP:

Pre-exposure prophylaxis (PrEP) is an essential tool in preventing HIV transmission among vulnerable populations. GSK has developed a long-acting injectable PrEP drug, which offers an extended duration of protection compared to conventional daily oral PrEP. By partnering with Viatris, Cipla, and Aurobindo, GSK aims to make this innovative long-acting PrEP more accessible and affordable for individuals at risk of HIV worldwide.

2. Increasing Affordability and Availability:

The collaboration between GSK, Viatris, Cipla, and Aurobindo is expected to lower the cost of long-acting PrEP by producing generic versions of GSK’s drug. Generic medications have the potential to significantly reduce drug costs, making them more affordable for patients and increasing access to life-saving treatments. The availability of generic long-acting PrEP could help overcome financial barriers and expand access to individuals in low- and middle-income countries where HIV prevalence is high.

3. Addressing Global HIV Epidemic:

The World Health Organization (WHO) estimates that over 38 million people worldwide are living with HIV. Access to affordable and effective prevention methods is crucial to curbing the HIV epidemic. The partnership between GSK, Viatris, Cipla, and Aurobindo represents a step forward in addressing this global challenge. By providing a more affordable long-acting PrEP option, these companies are contributing to the fight against HIV and facilitating greater access to prevention for vulnerable communities.

4. Expanding the PrEP Landscape:

The availability of generic versions of GSK’s long-acting PrEP drug will expand the options for individuals seeking HIV prevention methods. Currently, oral PrEP is the most widely used form of pre-exposure prophylaxis. However, the long-acting injectable PrEP offers advantages such as greater convenience, improved adherence, and reduced pill burden. The introduction of generic long-acting PrEP will provide individuals with additional choices, potentially increasing uptake and adherence to this critical HIV prevention strategy.

5. Collaborative Efforts for Global Impact:

The partnership between GSK, Viatris, Cipla, and Aurobindo showcases the power of collaboration in addressing global health challenges. By combining resources, expertise, and manufacturing capabilities, these companies are working towards a common goal of reducing the burden of HIV and expanding access to prevention tools. This collaborative approach can serve as a model for addressing other global health priorities and accelerating progress towards achieving Sustainable Development Goal 3 – “Ensure healthy lives and promote well-being for all at all ages.”

6. Regulatory and Supply Chain Considerations:

The production and distribution of generic long-acting PrEP drugs require regulatory approvals and robust supply chains to ensure widespread availability. All partners involved will need to navigate regulatory processes efficiently and collaborate to overcome potential challenges in scaling up production and distribution. Close coordination between GSK, Viatris, Cipla, and Aurobindo will be crucial to meet the increased demand for long-acting PrEP and achieve the desired impact on HIV prevention globally.


The partnership between GSK, Viatris, Cipla, and Aurobindo to produce generic versions of GSK’s long-acting PrEP drug marks a significant step towards expanding access to HIV prevention. By making this innovative prevention tool more affordable and available, the collaboration aims to reduce the impact of HIV on vulnerable populations. This effort exemplifies the power of collaboration and holds the potential to accelerate progress in achieving global HIV prevention targets. The increased availability of long-acting PrEP will contribute to the fight against HIV and bring us closer to a world free from the burden of this devastating disease.